Seeking Alpha

Theralink® Technologies Achieves the First College of American Pathologists Accreditation for a Commercial Reverse Phase Protein Array Laboratory in U.S.

GOLDEN, Colo., Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (THER) (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast ...
Seeking Alpha

Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant ...

Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (THER) (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse ...
GEN

Protein Microarrays See Broader Utilization

Protein microarrays are one aspect of highly automated, large-scale biological screening technologies, the other is nucleic acid arrays. As DNA arrays reveal their origin in Southern blotting ...
ascopubs.org

Approaches and data needed for real-world evaluation of multicancer early detection tests.

Interim analysis examining the feasibility of incorporating laser microdissection enrichment of tumor specimens and reverse phase protein array analysis with next generation sequencing into a ...
ascopubs.org

Utilization of germline testing in patients with early-onset pancreatic cancer (EOPC).

Proteomic quantification of HER-2 abundance and activation in pancreatic ductal adenocarcinoma tumor specimens using reverse phase protein array. Combination of 5-FU plus KRAS G12D inhibitor MRTX1133 ...